234 related articles for article (PubMed ID: 20072663)
1. Sex-specific impact of aldosterone receptor antagonism on ventricular remodeling and gene expression after myocardial infarction.
Kanashiro-Takeuchi RM; Heidecker B; Lamirault G; Dharamsi JW; Hare JM
Clin Transl Sci; 2009 Apr; 2(2):134-42. PubMed ID: 20072663
[TBL] [Abstract][Full Text] [Related]
2. Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction.
Fraccarollo D; Galuppo P; Hildemann S; Christ M; Ertl G; Bauersachs J
J Am Coll Cardiol; 2003 Nov; 42(9):1666-73. PubMed ID: 14607457
[TBL] [Abstract][Full Text] [Related]
3. [Additive improvement of left ventricular remodeling by aldosterone receptor blockade with eplerenone and angiotensin II type 1 receptor antagonist in rats with myocardial infarction].
Yoshiyama M; Omura T; Yoshikawa J
Nihon Yakurigaku Zasshi; 2004 Aug; 124(2):83-9. PubMed ID: 15277726
[TBL] [Abstract][Full Text] [Related]
4. Additive amelioration of left ventricular remodeling and molecular alterations by combined aldosterone and angiotensin receptor blockade after myocardial infarction.
Fraccarollo D; Galuppo P; Schmidt I; Ertl G; Bauersachs J
Cardiovasc Res; 2005 Jul; 67(1):97-105. PubMed ID: 15949473
[TBL] [Abstract][Full Text] [Related]
5. Effects of eplerenone on transcriptional factors and mRNA expression related to cardiac remodelling after myocardial infarction.
Enomoto S; Yoshiyama M; Omura T; Matsumoto R; Kusuyama T; Kim S; Izumi Y; Akioka K; Iwao H; Takeuchi K; Yoshikawa J
Heart; 2005 Dec; 91(12):1595-600. PubMed ID: 15797934
[TBL] [Abstract][Full Text] [Related]
6. Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction.
Udelson JE; Feldman AM; Greenberg B; Pitt B; Mukherjee R; Solomon HA; Konstam MA
Circ Heart Fail; 2010 May; 3(3):347-53. PubMed ID: 20299607
[TBL] [Abstract][Full Text] [Related]
7. Left ventricular remodeling after acute myocardial infarction: does eplerenone have an effect?
Weir RA; Mark PB; Petrie CJ; Clements S; Steedman T; Ford I; Ng LL; Squire IB; Wagner GS; McMurray JJ; Dargie HJ
Am Heart J; 2009 Jun; 157(6):1088-96. PubMed ID: 19464421
[TBL] [Abstract][Full Text] [Related]
8. Effect of a selective aldosterone receptor antagonist in myocardial infarction.
Delyani JA; Robinson EL; Rudolph AE
Am J Physiol Heart Circ Physiol; 2001 Aug; 281(2):H647-54. PubMed ID: 11454568
[TBL] [Abstract][Full Text] [Related]
9. Spironolactone modulates expressions of cardiac mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase 2 and prevents ventricular remodeling in post-infarct rat hearts.
Takeda M; Tatsumi T; Matsunaga S; Hayashi H; Kimata M; Honsho S; Nishikawa S; Mano A; Shiraishi J; Yamada H; Takahashi T; Matoba S; Kobara M; Matsubara H
Hypertens Res; 2007 May; 30(5):427-37. PubMed ID: 17587755
[TBL] [Abstract][Full Text] [Related]
10. Effects of eplerenone and salt intake on left ventricular remodeling after myocardial infarction in rats.
Urabe A; Izumi T; Abe Y; Taniguchi I; Mochizuki S
Hypertens Res; 2006 Aug; 29(8):627-34. PubMed ID: 17137219
[TBL] [Abstract][Full Text] [Related]
11. Eplerenone, a selective aldosterone blocker, improves diastolic function in aged rats with small-to-moderate myocardial infarction.
Masson S; Staszewsky L; Annoni G; Carlo E; Arosio B; Bai A; Calabresi C; Martinoli E; Salio M; Fiordaliso F; Scanziani E; Rudolph AE; Latini R
J Card Fail; 2004 Oct; 10(5):433-41. PubMed ID: 15470655
[TBL] [Abstract][Full Text] [Related]
12. Aldosterone and cortisol predict medium-term left ventricular remodelling following myocardial infarction.
Weir RA; Tsorlalis IK; Steedman T; Dargie HJ; Fraser R; McMurray JJ; Connell JM
Eur J Heart Fail; 2011 Dec; 13(12):1305-13. PubMed ID: 21940729
[TBL] [Abstract][Full Text] [Related]
13. The TBX1 Transcription Factor in Cardiac Remodeling After Myocardial Infarction.
Sánchez-Más J; Lax A; Asensio-López MC; Fernández-Del Palacio MJ; Caballero L; Navarro-Peñalver M; Pérez-Martínez MT; Gimeno-Blanes JR; Pascual-Figal DA
Rev Esp Cardiol (Engl Ed); 2016 Nov; 69(11):1042-1050. PubMed ID: 27422448
[TBL] [Abstract][Full Text] [Related]
14. Role of a selective aldosterone blocker in mice with chronic heart failure.
Wang D; Liu YH; Yang XP; Rhaleb NE; Xu J; Peterson E; Rudolph AE; Carretero OA
J Card Fail; 2004 Feb; 10(1):67-73. PubMed ID: 14966777
[TBL] [Abstract][Full Text] [Related]
15. Mineralocorticoid receptor antagonists modulate galectin-3 and interleukin-33/ST2 signaling in left ventricular systolic dysfunction after acute myocardial infarction.
Lax A; Sanchez-Mas J; Asensio-Lopez MC; Fernandez-Del Palacio MJ; Caballero L; Garrido IP; Pastor-Perez FJ; Januzzi JL; Pascual-Figal DA
JACC Heart Fail; 2015 Jan; 3(1):50-58. PubMed ID: 25458175
[TBL] [Abstract][Full Text] [Related]
16. Effects of eplerenone, a selective aldosterone blocker, on the progression of left ventricular dysfunction and remodeling in rats with dilated cardiomyopathy.
Wahed MI; Watanabe K; Ma M; Yamaguchi K; Takahashi T; Tachikawa H; Kodama M; Aizawa Y
Pharmacology; 2005 Feb; 73(2):81-8. PubMed ID: 15467302
[TBL] [Abstract][Full Text] [Related]
17. Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure.
Suzuki G; Morita H; Mishima T; Sharov VG; Todor A; Tanhehco EJ; Rudolph AE; McMahon EG; Goldstein S; Sabbah HN
Circulation; 2002 Dec; 106(23):2967-72. PubMed ID: 12460880
[TBL] [Abstract][Full Text] [Related]
18. New treatment option for heart failure patients: eplerenone.
Southworth MR; Cavallari LH
J Cardiovasc Nurs; 2004; 19(6):390-5. PubMed ID: 15529060
[TBL] [Abstract][Full Text] [Related]
19. Critical role of CNS effects of aldosterone in cardiac remodeling post-myocardial infarction in rats.
Lal A; Veinot JP; Leenen FH
Cardiovasc Res; 2004 Dec; 64(3):437-47. PubMed ID: 15537497
[TBL] [Abstract][Full Text] [Related]
20. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats.
Nagata K; Obata K; Xu J; Ichihara S; Noda A; Kimata H; Kato T; Izawa H; Murohara T; Yokota M
Hypertension; 2006 Apr; 47(4):656-64. PubMed ID: 16505208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
